摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-[2-((N-methylsulfamoyl)amino)-3-fluoropyridin-4-ylmethyl]-4-methyl-7-phenoxychromen-2-one | 1548889-68-4

中文名称
——
中文别名
——
英文名称
3-[2-((N-methylsulfamoyl)amino)-3-fluoropyridin-4-ylmethyl]-4-methyl-7-phenoxychromen-2-one
英文别名
3-[[3-Fluoro-2-(methylsulfamoylamino)pyridin-4-yl]methyl]-4-methyl-7-phenoxychromen-2-one;3-[[3-fluoro-2-(methylsulfamoylamino)pyridin-4-yl]methyl]-4-methyl-7-phenoxychromen-2-one
3-[2-((N-methylsulfamoyl)amino)-3-fluoropyridin-4-ylmethyl]-4-methyl-7-phenoxychromen-2-one化学式
CAS
1548889-68-4
化学式
C23H20FN3O5S
mdl
——
分子量
469.493
InChiKey
FXNBBQANCQCLGY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    636.8±65.0 °C(predicted)
  • 密度:
    1.428±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.3
  • 重原子数:
    33
  • 可旋转键数:
    7
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.13
  • 拓扑面积:
    115
  • 氢给体数:
    2
  • 氢受体数:
    9

反应信息

点击查看最新优质反应信息

文献信息

  • Optimizing the Physicochemical Properties of Raf/MEK Inhibitors by Nitrogen Scanning
    作者:Toshihiro Aoki、Ikumi Hyohdoh、Noriyuki Furuichi、Sawako Ozawa、Fumio Watanabe、Masayuki Matsushita、Masahiro Sakaitani、Kenji Morikami、Kenji Takanashi、Naoki Harada、Yasushi Tomii、Koji Shiraki、Kentaro Furumoto、Mitsuyasu Tabo、Kiyoshi Yoshinari、Kazutomo Ori、Yuko Aoki、Nobuo Shimma、Hitoshi Iikura
    DOI:10.1021/ml400379x
    日期:2014.4.10
    Substituting a carbon atom with a nitrogen atom (nitrogen substitution) on an aromatic ring in our leads 1 la and 13g by applying nitrogen scanning afforded a set of compounds that improved not only the solubility but also the metabolic stability. The impact after nitrogen substitution on interactions between a derivative and its on- and off-target proteins (Raf/MEK, CYPs, and hERG channel) was also detected, most of them contributing to weaker interactions. After identifying the positions that kept inhibitory activity on HCT116 cell growth and Raf/MEK, compound I (CH5126766/RO5126766) was selected as a clinical compound. A phase I clinical trial is ongoing for solid cancers.
查看更多